Literature DB >> 25226290

Serum thyroglobulin (Tg) monitoring of patients with differentiated thyroid cancer using sensitive (second-generation) immunometric assays can be disrupted by false-negative and false-positive serum thyroglobulin autoantibody misclassifications.

Carole Spencer1, Ivana Petrovic, Shireen Fatemi, Jonathan LoPresti.   

Abstract

CONTEXT: Reliable thyroglobulin (Tg) autoantibody (TgAb) detection before Tg testing for differentiated thyroid cancer (DTC) is critical when TgAb status (positive/negative) is used to authenticate sensitive second-generation immunometric assay ((2G)IMA) measurements as free from TgAb interference and when reflexing "TgAb-positive" sera to TgAb-resistant, but less sensitive, Tg methodologies (radioimmunoassay [RIA] or liquid chromatography-tandem mass spectrometry [LC-MS/MS]).
OBJECTIVE: The purpose of this study was to assess how different Kronus (K) vs Roche (R) TgAb method cutoffs for "positivity" influence false-negative vs false-positive serum TgAb misclassifications that may reduce the clinical utility of reflex Tg testing.
METHODS: Serum Tg(2G)IMA, TgRIA, and TgLC-MS/MS measurements for 52 TgAb-positive and 37 TgAb-negative patients with persistent/recurrent DTC were compared. A total of 1426 DTC sera with TgRIA of ≥ 1.0 μg/L had false-negative and false-positive TgAb frequencies determined using low Tg(2G)IMA/TgRIA ratios (<75%) to indicate TgAb interference.
RESULTS: TgAb-negative patients with disease displayed Tg(2G)IMA, TgRIA, and TgLC-MS/MS serum discordances (% coefficient of variation = 24 ± 20%, range, 0%-100%). Of the TgAb-positive patients with disease, 98% had undetectable/lower Tg(2G)IMA vs either TgRIA or TgLC-MS/MS (P < .01), whereas 8 of 52 (15%) had undetectable Tg(2G)IMA + TgLC-MS/MS associated with TgRIA of ≥ 1.0 μg/L. Receiver operating characteristic curve analysis reported more sensitivity for TgAb method K vs R (81.9% vs 69.1%, P < .001), but receiver operating characteristic curve cutoffs (>0.6 kIU/L [K] vs >40 kIU/L [R]) had unacceptably high false-negative frequencies (22%-32%), whereas false positives approximated 12%. Functional sensitivity cutoffs minimized false negatives (13.5% [K] vs 21.3% [R], P < .01) and severe interferences (Tg(2G)IMA, <0.10 μg/L) (0.7% [K] vs 2.4% [R], P < .05) but false positives approximated 23%.
CONCLUSIONS: Reliable detection of interfering TgAbs is method and cutoff dependent. No cutoff eliminated both false-negative and false-positive TgAb misclassifications. Functional sensitivity cutoffs were optimal for minimizing false negatives but have inherent imprecision (20% coefficient of variation) that, exacerbated by TgAb biologic variability during DTC monitoring, could cause TgAb status to fluctuate for patients with low TgAb concentrations, prompting unnecessary Tg method changes and disrupting Tg monitoring. Laboratories using reflexing should limit Tg method changes by considering a patient's Tg + TgAb testing history in addition to current TgAb status before Tg method selection.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25226290      PMCID: PMC4297889          DOI: 10.1210/jc.2014-1203

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  68 in total

1.  Efficacy of ultrasound-guided percutaneous ethanol injection treatment in patients with a limited number of metastatic cervical lymph nodes from papillary thyroid carcinoma.

Authors:  Arne Heilo; Eva Sigstad; Kristin Holgersen Fagerlid; Olav Inge Håskjold; Krystyna Kotanska Grøholt; Aasmund Berner; Trine Bjøro; Lars H Jørgensen
Journal:  J Clin Endocrinol Metab       Date:  2011-06-29       Impact factor: 5.958

2.  Clinical aggressiveness and long-term outcome in patients with papillary thyroid cancer and circulating anti-thyroglobulin autoantibodies.

Authors:  Cosimo Durante; Sara Tognini; Teresa Montesano; Fabio Orlandi; Massimo Torlontano; Efisio Puxeddu; Marco Attard; Giuseppe Costante; Salvatore Tumino; Domenico Meringolo; Rocco Bruno; Fabiana Trulli; Maria Toteda; Adriano Redler; Giuseppe Ronga; Sebastiano Filetti; Fabio Monzani
Journal:  Thyroid       Date:  2014-05-21       Impact factor: 6.568

3.  The behavior of autologous thyroglobulin in the circulation of rabbits immunized with either heterologous or altered homologous thyroglobulin.

Authors:  W O Weigle; G J High
Journal:  J Immunol       Date:  1967-06       Impact factor: 5.422

Review 4.  Clinical review: Clinical utility of thyroglobulin antibody (TgAb) measurements for patients with differentiated thyroid cancers (DTC).

Authors:  Carole A Spencer
Journal:  J Clin Endocrinol Metab       Date:  2011-09-14       Impact factor: 5.958

5.  Risk-adapted management of differentiated thyroid cancer assessed by a sensitive measurement of basal serum thyroglobulin.

Authors:  Pasqualino Malandrino; Adele Latina; Salvatore Marescalco; Angela Spadaro; Concetto Regalbuto; Rosa Anna Fulco; Claudia Scollo; Riccardo Vigneri; Gabriella Pellegriti
Journal:  J Clin Endocrinol Metab       Date:  2011-03-30       Impact factor: 5.958

6.  Undetectable sensitive serum thyroglobulin (<0.1 ng/ml) in 163 patients with follicular cell-derived thyroid cancer: results of rhTSH stimulation and neck ultrasonography and long-term biochemical and clinical follow-up.

Authors:  A M Chindris; N N Diehl; J E Crook; V Fatourechi; R C Smallridge
Journal:  J Clin Endocrinol Metab       Date:  2012-05-25       Impact factor: 5.958

7.  Thyroglobulin and anti-thyroglobulin assays in thyroid cancer monitoring.

Authors:  John Krahn; Tom Dembinski
Journal:  Clin Biochem       Date:  2009-01-03       Impact factor: 3.281

8.  Discordance in thyroglobulin measurements by radioimmunoassay and immunometric assay: a useful means of identifying thyroglobulin assay interference.

Authors:  Michael S Crane; Mark W J Strachan; Anthony D Toft; Geoffrey J Beckett
Journal:  Ann Clin Biochem       Date:  2013-07-11       Impact factor: 2.057

9.  A novel mass spectrometry-based assay for the accurate measurement of thyroglobulin from patient samples containing antithyroglobulin autoantibodies.

Authors:  Nigel J Clarke; Yanni Zhang; Richard E Reitz
Journal:  J Investig Med       Date:  2012-12       Impact factor: 2.895

10.  Sequential changes of serum antithyroglobulin antibody levels are a good predictor of disease activity in thyroglobulin-negative patients with papillary thyroid carcinoma.

Authors:  Ching-Jung Hsieh; Pei-Wen Wang
Journal:  Thyroid       Date:  2013-11-13       Impact factor: 6.568

View more
  27 in total

1.  Risk Stratification in Differentiated Thyroid Cancer: From Detection to Final Follow-up.

Authors:  R Michael Tuttle; Ali S Alzahrani
Journal:  J Clin Endocrinol Metab       Date:  2019-03-15       Impact factor: 5.958

2.  Thyroglobulin Liquid Chromatography-Tandem Mass Spectrometry Has a Low Sensitivity for Detecting Structural Disease in Patients with Antithyroglobulin Antibodies.

Authors:  Umal Azmat; Kyle Porter; Leigha Senter; Matthew D Ringel; Fadi Nabhan
Journal:  Thyroid       Date:  2016-11-09       Impact factor: 6.568

3.  First Steps toward Harmonization of LC-MS/MS Thyroglobulin Assays.

Authors:  Brian C Netzel; Russell P Grant; Andrew N Hoofnagle; Alan L Rockwood; Christopher M Shuford; Stefan K G Grebe
Journal:  Clin Chem       Date:  2015-10-01       Impact factor: 8.327

4.  Thyroglobulin (Tg) Testing Revisited: Tg Assays, TgAb Assays, and Correlation of Results With Clinical Outcomes.

Authors:  Brian C Netzel; Stefan K G Grebe; B Gisella Carranza Leon; M Regina Castro; Penelope M Clark; Andrew N Hoofnagle; Carole A Spencer; Adina F Turcu; Alicia Algeciras-Schimnich
Journal:  J Clin Endocrinol Metab       Date:  2015-06-16       Impact factor: 5.958

5.  Disease Burden and Outcome in Children and Young Adults With Concurrent Graves Disease and Differentiated Thyroid Carcinoma.

Authors:  Suzanne P MacFarland; Andrew J Bauer; N Scott Adzick; Lea F Surrey; Jessica Noyes; Ken Kazahaya; Sogol Mostoufi-Moab
Journal:  J Clin Endocrinol Metab       Date:  2018-08-01       Impact factor: 5.958

6.  Prognostic value of change in anti-thyroglobulin antibodies after thyroidectomy in patients with papillary thyroid carcinoma.

Authors:  A Ernaga-Lorea; M C Hernández-Morhain; E Anda-Apiñániz; J J Pineda-Arribas; I Migueliz-Bermejo; N Eguílaz-Esparza; A Irigaray-Echarri
Journal:  Clin Transl Oncol       Date:  2017-10-25       Impact factor: 3.405

7.  Dynamics of serum antithyroglobulin antibodies in patients with differentiated thyroid cancer.

Authors:  Fernanda Bueno; María Gabriela García Falcone; Mirna Angela Peñaloza; Erika Abelleira; Fabián Pitoia
Journal:  Endocrine       Date:  2019-10-24       Impact factor: 3.633

8.  Downregulation of LSD1 suppresses the proliferation, tumorigenicity and invasion of papillary thyroid carcinoma K1 cells.

Authors:  Ling-Ling Kong; Dong-Mei Man; Tian Wang; Guo-An Zhang; Wen Cui
Journal:  Oncol Lett       Date:  2016-02-18       Impact factor: 2.967

9.  A Study on Serum Antithyroglobulin Antibodies Interference in Thyroglobulin Measurement in Fine-Needle Aspiration for Diagnosing Lymph Node Metastasis in Postoperative Patients.

Authors:  Hyun Joo Shin; Hye Sun Lee; Eun-Kyung Kim; Hee Jung Moon; Ji Hye Lee; Jin Young Kwak
Journal:  PLoS One       Date:  2015-06-29       Impact factor: 3.240

10.  High Thyroglobulin Antibody Levels Increase the Risk of Differentiated Thyroid Carcinoma.

Authors:  Jing Qin; Zhenqian Yu; Haixia Guan; Liangfeng Shi; Yongping Liu; Na Zhao; Zhongyan Shan; Cheng Han; Yushu Li; Weiping Teng
Journal:  Dis Markers       Date:  2015-10-27       Impact factor: 3.434

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.